eguzman9@hboi.fau.edu
(772) 465-2400 ext 452

Education

2004, Ph.D. Immunology,
University of Texas MD Anderson Cancer Center, Houston, Texas.

1996, B.S. Molecular Biology/Biotechnology,
Salem-Teikyo University, Salem, West Virginia.

Career

1993 Student Fellow; Howard Hughes Medical Institute Summer Fellowship; West Virginia University, Morgantown, West Virginia

1995-1996 Independent Researcher, Salem-Teikyo University, Salem, West Virginia

1996-1997 Graduate Research Assistant, Theoretical Biology and Biophysics Division; HIV Database, Los Alamos National Laboratory, Los Alamos, New Mexico

1997-2001 Graduate Research Assistant, University of Texas M.D. Anderson Cancer Center, Houston, Texas

2001-2004 Graduate Research Assistant, University of California, Riverside, California

2004- 2005 Postdoctoral Fellow, Henry Ford Health System, Detroit, Michigan

2005-2007 Postdoctoral Investigator, Harbor Branch Oceanographic Institution, Ft.Pierce, Florida

2007 Assistant Research Scientist, Harbor Branch Oceanographic Institution, Ft. Pierce, Florida

2008-present Assistant Research Professor Harbor Branch Oceanographic Institute at FAU

Detailed CV

Research Interests

Dr. Guzmán joined the drug discovery program at Harbor Branch in 2005 as a Postdoctoral Investigator where she has performed research aimed at the discovery of novel cancer therapeutics including both development of novel molecular target based assays and determination of the mechanism of action of compounds discovered at HBOI. In 2007, Dr. Guzmán became the leader of the cell biology program at the Center for Marine Biomedical and Biotechnology Research at HBOI. This program focuses on drug discovery for pancreatic cancer. New focuses will target cancer stem cells in pancreatic, breast and other cancers, as well as components of the immune system that are abnormal in most cancers. Her work at Harbor Branch has resulted in the discovery of novel anti-metastatic properties for manzamine A; the inhibition of topoisomerase II by isobatzelline E; the activation of Chk1/2 kinase and subsequent block of cell proliferation by aphrocallistin and the development of assays to detect compounds that target the MAP kinase pathway, GSK3β, NFKB, and survivin. This work has resulted in the filing of two provisional patents, a peer reviewed publication and three manuscripts currently in preparation.